Sanofi | SNY - Srodki Pieniężne I Ekwiwalent





Srodki Pieniężne I Ekwiwalent Zmiana Data
AbbVie USD 9.39B 4.16B 2026-03
Amgen USD 12.04B 2.91B 2026-03
AstraZeneca USD 7.56B 1.85B 2026-03
Bristol-Myers Squibb USD 9.57B 635M 2026-03
Canopy Growth CAD 364.68M 6.64M 2026-03
Corcept Therapeutics USD 108.74M 11.76M 2026-03
Drreddys Laboratories INR 15.37B 3.29B 2026-03
Eli Lilly USD 5.28B 1.99B 2026-03
Genmab DKK 1.72B 46M 2025-12
GlaxoSmithKline GBP 3.44B 292M 2026-03
Glaxosmithkline GBP 3.44B 146M 2026-03
J&J USD 21.69B 1.98B 2026-03
Lakefront Biotherapeutics EUR 66.8M 21.06M 2026-03
Merck USD 5.33B 9.24B 2026-03
Novartis USD 6.88B 4.56B 2026-03
Novartis USD 6.88B 2.68B 2026-03
Pacira USD 144.31M 14.24M 2026-03
Perrigo USD 531.6M 99.5M 2025-12
Pfizer USD 1.7B 561M 2026-03
Phibro Animal Health USD 54.93M 557K 2026-03
Prestige Brands USD 63.87M 1.5M 2026-03
Roche Holding CHF 7.55B 579M 2025-06
Sanofi EUR 7.66B 1.25B 2025-12
Sanofi EUR 5.54B 2.11B 2026-03
Supernus Pharmaceuticals USD 184.87M 56.42M 2026-03
UCB EUR 1.57B 1.14B 2024-12
Zoetis USD 1.94B 369M 2026-03